A study of PD-L1 expression in intravascular large B cell lymphoma: correlation with clinical and pathological features
A study of PD-L1 expression in intravascular large B cell lymphoma: correlation with clinical and pathological features
复制标题
DOI：
10.1111/his.13870
复制
发表时间：
2019-08-01
期刊：
影响因子：
6.4
通讯作者：
Pittaluga, Stefania
中科院分区：
文献类型：
--
作者：
Gupta, Gaurav K.;Jaffe, Elaine S.;Pittaluga, Stefania
血管内大 B 细胞淋巴瘤 (IVLBCL) 是一种罕见的、侵袭性的结外大 B 细胞淋巴瘤，其特征是肿瘤细胞在血管腔（特别是毛细血管）内生长。程序性细胞死亡配体 1 (PD-L1) 是一种细胞表面糖蛋白，可与 T 细胞表面的程序性死亡 1 (PD-1) 相互作用，从而调节免疫反应。 PD-L1 是一种可靶向的免疫检查点分子，在多种癌症（包括一部分淋巴瘤）的肿瘤细胞上表达。我们将 PD-L1 的表达与这种罕见疾病的临床和病理结果相关联。美国国立卫生研究院 (NIH) 国家癌症研究所病理学实验室档案中发现了 11 例 IVLBCL 病例。进行了一组免疫染色（CD20、CD3、CD5、PD-L1）。根据 2017 年发布的 WHO 标准，这些病例被归类为经典型或与噬血细胞综合征 (HPS) 相关的变异型。 3例（27.3%）为HPS变异型，8例（72.7%）为经典型。 11例中有5例（45.5%）CD5阳性；三分之二 (66%) 是 HPS 变体，八分之三 (37.5%) 是经典形式。总体而言，9 个可评估病例中有 4 个 (44.4%) PD-L1 呈阳性，其中 3 个为经典病例。只有一个 CD5 阳性病例是 PD-L1 阳性，这是一种经典变异。总之，IVLBCL 的一个子集表达 PD-L1。尽管有限，但这些数据表明 PD-L1 以所谓的经典形式和 HPS 变体表达。 PD-L1 的表达与 CD5 的表达无关。最后，在部分 IVLBCL 淋巴瘤病例中检测 PD-L1 表达可能会识别出可能受益于靶向免疫治疗的患者。
Intravascular large B cell lymphoma (IVLBCL) is a rare, aggressive, extranodal large B cell lymphoma characterised by growth of tumour cells within the lumen of vessels, particularly capillaries. Programmed cell death ligand 1 (PD-L1) is a cell surface glycoprotein that interacts with programmed death 1 (PD-1) on the T cell surface, leading to modulation of the immune response. PD-L1 is a targetable immune check-point molecule that is expressed on neoplastic cells in various cancers, including a subset of lymphomas. We correlated the expression of PD-L1 with clinical and pathological findings in this rare disease. Eleven cases of IVLBCL were identified in the archives of Laboratory of Pathology at the National Cancer Institute, NIH. A panel of immunostains (CD20, CD3, CD5, PD-L1) was performed. The cases were classified as the classic form or the variant associated with haemophagocytic syndrome (HPS) based on published 2017 WHO criteria. Three cases (27.3%) were HPS variant and eight cases (72.7%) were the classic form. Five (45.5%) of 11 cases were CD5-positive; two of three (66%) were HPS variants and three of eight (37.5%) were classic form. Overall, four of nine evaluable cases (44.4%) were positive for PD-L1, three of which were classic. Only one CD5-positive case was PD-L1-positive, a classic variant. In summary, a subset of IVLBCL express PD-L1. Although limited, these data suggest that PD-L1 is expressed in both the so-called classic form as well as the HPS variant. PD-L1 is expressed irrespective of CD5 expression. Finally, detection of PD-L1 expression in a subset of IVLBCL lymphoma cases may identify patients who might benefit from targeted immunotherapy.